Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2024-04-02 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
VOYDEYA APPROVED IN US
Foreign Filer Report
2024-04-02 English
FDA ACCEPTS DATO-DXD BLA FOR BREAST CANCER
Foreign Filer Report
2024-04-02 English
Voydeya approved in US
Regulatory Filings Classification · 1% confidence The document starts with 'RNS Number : 8967I' and concludes with information about RNS, the news service of the London Stock Exchange, and mentions the Financial Conduct Authority. This strongly indicates a regulatory news service announcement. The content details the US FDA approval of a drug (Voydeya) and provides extensive background on the drug, the disease (PNH), and clinical trial results. While it contains detailed information, its format and source attribution (RNS) suggest it is a formal regulatory announcement rather than a comprehensive annual report (10-K), an interim report (IR), or a management discussion (MDA). Since it is a specific, material announcement distributed via the official regulatory news channel, it fits best under the general 'Regulatory Filings' category (RNS), which serves as the fallback for official, non-periodic announcements that don't fit other specific codes like ER or DIV. It is not a short announcement pointing to an attached report, as the core information is present, but RNS is the most appropriate classification for this type of market-sensitive regulatory news release.
2024-04-02 English
FDA accepts Dato-DXd BLA for breast cancer
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated '02 April 2024'. It contains a headline announcing the acceptance of a Biologics License Application (BLA) by the US FDA for a drug, followed by detailed scientific and commercial information regarding this regulatory event. The presence of 'RNS Number' and the concluding boilerplate text referencing 'RNS, the news service of the London Stock Exchange' strongly indicates this is a regulatory news service announcement. Since this is a specific announcement about a regulatory action (BLA acceptance) and not a full financial report (like 10-K or IR) or a general press release, it fits best under the general 'Regulatory Filings' category, which serves as the fallback for specific regulatory news that isn't covered by other codes like DIV or DIRS. Given the context of regulatory news distribution, RNS is the most appropriate code.
2024-04-02 English
ULTOMIRIS APPROVED IN THE US FOR NMOSD
Foreign Filer Report
2024-03-25 English
Ultomiris approved in the US for NMOSD
Regulatory Filings Classification · 1% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement, indicated by the 'RNS Number' field and the concluding boilerplate text referencing RNS and the London Stock Exchange. The content is a press release announcing the US FDA approval of a drug (Ultomiris) for a specific condition (NMOSD), including clinical trial data and management commentary. This type of broad, immediate regulatory announcement that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified as a general Regulatory Filing or Announcement. Since 'RNS' is an explicit category for general regulatory announcements, it is the most appropriate fit, especially given the source identifier.
2024-03-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.